EGFR and cancer: By analyzing the whole transcriptome data retrieved from14, we identified several canonical cancer-associated pathways that were perturbed by CAP including 'PI3K/AKT and MAPK signalings' and 'EGFR tyrosine kinase inhibitor resistance' (Figure 2A).